Clinical Findings on RNAi‑Based Therapies Presented at the European Society of Cardiology Congress
Alnylam Pharmaceuticals detailed new clinical data supporting the use of its RNA interference (RNAi) platform in transthyretin (TTR) amyloidosis and hypertension. The presentations emphasized consistent efficacy across diverse patient populations, favorable safety profiles, and the regulatory trajectory of these agents.
1. Vutrisiran (AMVUTTRA) in Transthyretin Amyloidosis
1.1. Phase III HELIOS‑B Subgroup Analysis
A prespecified subgroup analysis of the HELIOS‑B Phase III study evaluated vutrisiran in patients who were either receiving or not receiving the stabilizer tafamidis at baseline. Key findings include:
- Cardiovascular Outcomes
- Vutrisiran reduced the composite risk of death and recurrent cardiovascular events in both monotherapy and combination cohorts, with hazard ratios consistently below 1.0 across subgroups.
- Functional Capacity
- The 6‑minute walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores improved or were maintained, indicating preserved functional capacity.
- Safety
- Incidence of treatment‑emergent adverse events (TEAEs) was comparable to placebo and to tafamidis alone. Gastrointestinal, neurological, and ocular events were notably lower in the vutrisiran group.
These data support the clinical flexibility of vutrisiran as a monotherapy or adjunct to tafamidis without compromising safety or efficacy.
1.2. Multisystemic Impact and Functional Reserve
A post‑hoc analysis introduced an intrinsic‑capacity composite score comprising mobility, cognition, vitality, psychological wellbeing, and sensory function. Findings:
- Decline Mitigation
- Patients on vutrisiran experienced a statistically significant smaller decline in composite scores (mean change −0.12 vs. −0.34 in control, p < 0.01).
- Clinical Relevance
- The preservation of intrinsic capacity suggests potential benefits for maintaining functional reserve and supporting healthy aging in TTR amyloidosis.
1.3. Sex‑Based Pooled Analysis
Four Phase III trials (including both vutrisiran and its predecessor patisiran) were pooled to examine sex differences:
- Outcome Consistency
- Men and women showed comparable reductions in NT‑proBNP, troponin‑T, and echocardiographic indices (e.g., left ventricular ejection fraction, wall thickness).
- Safety Uniformity
- TEAE rates, including injection‑site reactions and systemic events, did not differ significantly by sex.
The pooled evidence reinforces the broad applicability of RNAi‑mediated TTR silencing across sexes.
2. Zilebesiran in Uncontrolled Hypertension
2.1. Phase II Study Design
An exploratory Phase II trial evaluated zilebesiran, an RNAi agent targeting angiotensinogen, in patients with uncontrolled hypertension despite ≥ 3 antihypertensive medications.
2.2. Blood‑Pressure Outcomes
- Office Blood‑Pressure
- Mean systolic reduction: 12 mm Hg (95 % CI: 8–16).
- Ambulatory Monitoring
- Nighttime systolic reduction: 9 mm Hg (95 % CI: 5–13).
- Sustainability
- Blood‑pressure lowering effects persisted over 12 weeks without dose escalation.
2.3. Safety Profile
- Adverse Events
- TEAEs were predominantly mild or moderate. The most frequent were transient headache and fatigue.
- Serious Events
- No serious adverse events attributable to zilebesiran were reported.
The favorable safety and efficacy data have paved the way for a global Phase III cardiovascular outcomes trial, with endpoints including major adverse cardiovascular events (MACE).
3. Implications for Clinical Practice and Health Systems
| Aspect | Clinical Insight | Practical Implication |
|---|---|---|
| Efficacy Consistency | Vutrisiran demonstrates robust cardiovascular protection across tafamidis subgroups and sexes. | Enables broader prescribing across diverse patient profiles, simplifying treatment algorithms for TTR amyloidosis. |
| Safety Profile | TEAE rates lower than placebo/tafamidis; gastrointestinal, neurological, and ocular events minimized. | Reduces monitoring burden and supports patient adherence; may lower overall healthcare costs. |
| Functional Reserve | Preservation of intrinsic capacity composite scores. | Supports proactive management of frailty and early interventions to sustain quality of life. |
| Blood‑Pressure Control | Zilebesiran achieves meaningful reductions in uncontrolled hypertension. | Offers a novel mechanism for patients refractory to standard pharmacotherapies; could reduce downstream cardiovascular morbidity. |
| Regulatory Pathways | Phase III data bolster IND and NDA submissions; ongoing Phase III trials for zilebesiran. | Anticipated approvals may expand therapeutic options; reimbursement strategies should consider value‑based frameworks. |
4. Strategic Outlook
Alnylam’s presentations underscore a clear trajectory: leveraging RNAi technologies to address genetic drivers of cardiovascular disease. The company’s commitment to rigorous evidence generation, safety surveillance, and regulatory engagement positions it to deliver innovative therapies that could reshape treatment paradigms for transthyretin amyloidosis and hypertension. Healthcare systems should monitor forthcoming approvals and real‑world data to optimize integration of these agents into standard care pathways.
